OraSure Technologies, Inc. (OSUR)

Over the past six months, OraSure Technologies' stock price has fluctuated, with a 52-week low of $2.08 on November 21, 2025, and a 52-week high of $3.82 on July 14, 2025. As of early April 2026, the share price was around $3.08, representing a slight decline of 0.96% from April 4, 2025. Key events impacting the stock include the Q3 2025 earnings release, the BioMedomics acquisition, activist investor activity from Altai Capital Management, FDA submissions for a rapid molecular CT/NG self-test and Colli-Pee™, Q4 2025 financial results, and the OraQuick™ HIV Self-Test launch in Canada.

OraSure Technologies experiences demand seasonality for some products and services. Management anticipated a decline in Sample Management Solutions revenue in Q4 2025 due to seasonality and disruption from a key customer. The International Diagnostics business experienced a slower pace of orders in the second half of 2025, as in-country partners worked through existing inventory and national health programs adapted to changes in funding, indicating seasonality in international demand for HIV tests.

OraSure Technologies, Inc. is a medical device company based in Bethlehem, Pennsylvania, focused on developing, manufacturing, and marketing diagnostic products and sample management solutions. The company's key products include rapid diagnostic tests like the OraQuick® rapid HIV test, as well as tests for Hepatitis C and Ebola. OraSure also developed rapid, at-home coronavirus tests, such as the InteliSwab COVID-19 rapid test. Additionally, it provides genomic products under the Oragene and ORAcollect brands, Colli-Pee collection devices, and HEMAcollect protein blood collection devices. Through acquisitions like BioMedomics, OraSure has expanded its diagnostics portfolio to include tests like Sickle SCAN for sickle cell disease.

OraSure Technologies is headquartered in Bethlehem, Pennsylvania, which houses its largest employee base and a manufacturing facility. The company has expanded globally through acquisitions, including DNA Genotek Inc. in Ottawa, Canada, and Sherlock Biosciences with locations in Newton, Massachusetts, and the United Kingdom. OraSure's products are served worldwide, with regulatory clearances or approvals in key markets across North America, Europe, and Asia. The majority of its revenue comes from the United States.

OraSure Technologies' brand reputation has been influenced by its strategic transformation and engagement with activist investor Altai Capital Management. The company has been working to advance its strategic transformation, expand and diversify its product portfolio, and strengthen customer relationships. However, Altai Capital's public scrutiny regarding perceived underperformance has impacted brand reputation. OraSure's Board and management have responded by reaffirming their commitment to driving value and highlighting operational progress.

OraSure Technologies, Inc. is a publicly traded company on Nasdaq under the ticker OSUR, with ownership distributed among institutional, retail, and individual investors. Institutional investors hold a significant majority of its shares. As of April 9, 2026, 145 institutional owners held a total of 60,588,576 shares. Major institutional owners include BlackRock, Inc., Private Management Group Inc, Vanguard Group Inc, Neuberger Berman Group LLC, Altai Capital Management, L.P., Dimensional Fund Advisors Lp, Systematic Financial Management Lp, Renaissance Technologies Llc, Acadian Asset Management Llc, and Cannell Capital Llc. Approximately 5.49% of the company's stock is owned by insiders.